Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ambroxol→

Ambroxol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
18683-91-5
Molecular formula
C13H18Br2N2O
Molecular weight
378.1 g/mol
Drug class
Mucolyticsecretolytic and mucokinetic agent (bromhexine metabolite)
Mechanism of action
The precise mechanism is not fully elucidated. Ambroxol increases serous respiratory secretion, stimulates ciliary activity and mucociliary clearance, and activates pulmonary surfactant production, helping reduce mucus viscosity and facilitate expectoration.
Indications / reported uses
  • Expectorant use in acute and chronic respiratory conditions with abnormal viscid mucus, where authorised
  • Lozenge formulations may be used for sore throat; injectable uses and indications differ by product and jurisdiction

Sources: European Medicines Agency (EMA) referral · Spanish Agency of Medicines (AEMPS) SmPC

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ambroxol Environmental Risk Assessment (ERA) (the Ambroxol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.